CN1114431C - Medicine for treating atrophic gastritis and its preparing process - Google Patents
Medicine for treating atrophic gastritis and its preparing process Download PDFInfo
- Publication number
- CN1114431C CN1114431C CN00124366A CN00124366A CN1114431C CN 1114431 C CN1114431 C CN 1114431C CN 00124366 A CN00124366 A CN 00124366A CN 00124366 A CN00124366 A CN 00124366A CN 1114431 C CN1114431 C CN 1114431C
- Authority
- CN
- China
- Prior art keywords
- radix
- rhizoma
- atrophic gastritis
- medicament
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 41
- 208000016644 chronic atrophic gastritis Diseases 0.000 title claims abstract description 25
- 208000004300 Atrophic Gastritis Diseases 0.000 title claims abstract description 22
- 208000036495 Gastritis atrophic Diseases 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title abstract description 3
- 229940079593 drug Drugs 0.000 title description 8
- 238000011282 treatment Methods 0.000 claims abstract description 15
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000006187 pill Substances 0.000 claims abstract description 11
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 9
- 241000218176 Corydalis Species 0.000 claims abstract description 8
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 7
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims description 9
- 210000003038 endothelium Anatomy 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 235000012907 honey Nutrition 0.000 claims description 5
- 206010003694 Atrophy Diseases 0.000 claims description 3
- 208000007882 Gastritis Diseases 0.000 claims description 3
- 230000037444 atrophy Effects 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 244000205574 Acorus calamus Species 0.000 abstract 1
- 244000233890 Alisma plantago Species 0.000 abstract 1
- 235000017300 Alisma plantago Nutrition 0.000 abstract 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 abstract 1
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 235000003097 Artemisia absinthium Nutrition 0.000 abstract 1
- 240000001851 Artemisia dracunculus Species 0.000 abstract 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 abstract 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 235000011996 Calamus deerratus Nutrition 0.000 abstract 1
- 241000510667 Conioselinum Species 0.000 abstract 1
- 241001523681 Dendrobium Species 0.000 abstract 1
- 241000287828 Gallus gallus Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241000234435 Lilium Species 0.000 abstract 1
- 241000146029 Lindera aggregata Species 0.000 abstract 1
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 240000004064 Poterium sanguisorba Species 0.000 abstract 1
- 235000008291 Poterium sanguisorba Nutrition 0.000 abstract 1
- 235000008282 Sanguisorba officinalis Nutrition 0.000 abstract 1
- 241001530126 Scrophularia Species 0.000 abstract 1
- 240000000260 Typha latifolia Species 0.000 abstract 1
- 239000001138 artemisia absinthium Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 5
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- 210000001156 gastric mucosa Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 208000023652 chronic gastritis Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 208000018556 stomach disease Diseases 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010061164 Gastric mucosal lesion Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicine for treating atrophic gastritis and a preparing process thereof. The medicine is prepared from lily bulb, poria from yunnan of china, scrophularia, lindera root, water plantain, ophiopogon root, angelica, virgate wormwood herb, rhizoma corydalis, white peony alba, dendrobium, calamus, hemlock parsley, chicken gizzard-membrane, notoginseng, largehead atractylodes rhizome, garden burnet root and cattail pollen as raw materials which are proportionally prepared into pills. The present invention has unique formulation, and the effective rate of treatment reaches more than 95%.
Description
The present invention relates to a kind of medicament composition for the treatment of atrophic gastritis, particularly a kind of is the medicament of the treatment atrophic gastritis made of raw material with the vegetable Chinese herbal medicine.The invention still further relates to this medicaments preparation method.
Atrophic gastritis is common digestive system disease, and sickness rate is very high.This disease belongs to the scope of diseases such as Chinese medicine " stomachache ", " feeling of fullness ".Atrophic gastritis is a refractory disease, and medical circle is thought " the gastric mucosa atrophy is irreversible ".Pathological changes such as the intestinal epithelial metaplasia of atrophic gastritis and gastric epithelial cells, dysplasia are the gastric cancer pathological changes in early stage, further develop canceration can take place, thereby human beings'health and life in serious threat.
In the past, medical circle lacked the effect method of treatment atrophic gastritis, and doctor trained in Western medicine generally is a symptomatic treatment.The traditional Chinese medical science is with pharmaceutical treatments such as spleen-strengthening bolus, Fuzi Lizhong Wan, XIANGSHA YANGWEI WAN traditionally.With the XIANGSHA YANGWEI WAN is example, and its main component is Rhizoma Cyperi, Fructus Amomi, the Radix Aucklandiae, the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae, Poria etc.This medicine is based on the invigorating the spleen and benefiting QI warming middle-JIAO, though its relief of symptoms for the moment can not be cured atrophic gastritis, and symptom Chang Fanfu outbreak, gastric mucosal lesions also increases the weight of gradually.Therefore, the new drug of research healing atrophic gastritis is the important topic of medical circle.
The purpose of this invention is to provide a kind of various symptoms that can alleviate atrophic gastritis, the gastric mucosa body of gland of atrophy is recovered normally gradually, realize the medicament of effective therapeutic outcome.
The objective of the invention is to realize by following technical scheme:
A kind of medicament for the treatment of atrophic gastritis, it comprises following component, the content of each component unit is by weight counted (down together):
Bulbus Lilii 45-100; Radix Scrophulariae 60-100; Radix Linderae 30-60;
Radix Ophiopogonis 60-100; Radix Angelicae Sinensis 30-60; Radix Paeoniae Alba 75-180;
Herba Dendrobii 30-100; Rhizoma Chuanxiong 30-60;
The present invention can also add following adjuvant drug:
Poria 45-100; Rhizoma Alismatis 30-60; Herba Artemisiae Scopariae 45-75; Rhizoma Corydalis 45-75;
Rhizoma Acori Graminei 30-60; Endothelium corneum 10-45; Radix Notoginseng 10-45; Rhizoma Atractylodis Macrocephalae 25-60;
Radix Sanguisorbae 45-100; Pollen Typhae 30-75.
The medicament of above-mentioned treatment atrophic gastritis can be a said dosage form on any pharmaceutics, but the most convenient with pill on using.
Preparation method of the present invention is undertaken by following operation;
1. make up a prescription
By prescription the each component medicament is weighed.
2. selection
Each medicament is removed earth, choose clean impurity, drying.
3. pulverize
With above each medicament powder be broken into 80 order fine powders, sieve, mixing.
4. pill
Press medicated powder weight and add the equivalent refined honey, under 70 ℃ of temperature, make honeyed pill.
The present invention's patent medicine has the effect of regulating the stomach and sending down the abnormal ascending QI, spleen invigorating relieving distension, dredging collateral to stop pain,, belch vexed, indigestion and loss of appetite to atrophic gastritis and stomachache, distension, painful abdominal mass, symptom such as heartburn have better curative effect, this patent medicine has carried out clinical trial to routine chronic atrophic gastritis patient surplus 2500, and effective percentage is up to more than 95%.Clinical practice proves that this medicine not only has the good curing effect to atrophic gastritis, also gastric mucosa intestinalization and atypical hyperplasia is had the elimination effect, and is significant to the generation of prevention gastric cancer.
The invention will be further described below in conjunction with prescription and embodiment:
For disease of stomach such as chronic atrophic gastritis, the traditional Chinese medical science think traditionally taste altogether disease cause, thereby normal taste confuse opinion and control, by " weakness of the spleen and stomach ", " Deficiency and coldness of spleen and stomach " treatment.The present invention thinks that according to long-term clinical practice the spleen stomach function regulating respectively has its physiological characteristics and pathology characteristic, should not confuse opinion and control, and disease of stomach promptly should take the logical principle of falling of Liang Run to treat to control stomach.
The property of medicine of each medicament and function analysis are as follows in the prescription:
Bulbus Lilii, sweet flat nontoxic, go into brothers Yang Ming, lunar, the brothers' JUE YIN meridian of brothers, kind nourishing stomach-YIN has tall and erect the effect to yin deficiency and gastralgia, abdominal distention.The Radix Linderae, the acrid in the mouth temperature is nontoxic, goes into spleen, lung, kidney, urinary bladder channel, and the effect that pleasant, dissipating depression of QI is arranged, relieves the pain cures mainly the QI rising in reverse order chest and abdomen swelling and pain, and dyspepsia does not disappear, and food is told in regurgitation.Bulbus Lilii, the Radix Linderae be 5 one-tenths sides mutually, be apt to control have a stomach-ache, abdominal distention, be monarch drug altogether.
Radix Ophiopogonis, Herba Dendrobii, Radix Scrophulariae three health preserving with drugs Yin and promoting production of body liquid, the physiological property of just closing stomach liking moistness and disliking dryness.Radix Angelicae Sinensis, the bitter in the mouth temperature is nontoxic, goes into the heart, liver, spleen channel, the effect that has benefiting blood and regulating blood circulation, warming middle-JIAO to relieve the pain.The Radix Paeoniae Alba, bitter in the mouth is flat, goes into liver, spleen channel, have nourishing blood to suppress the hyperactive liver, slow in pain relieving, remove the merit of arthralgia due to stagnation of blood.According to pharmacological research, Radix Angelicae Sinensis all has good influence to substance metabolism, endocrine, blood circulation, and various bacteria such as dysentery bacterium, Hemolytic streptococcus are had antibacterial action.The Radix Paeoniae Alba has inhibitory action to bacillus pyocyaneus, Bacillus typhi, Diplococcus pneumoniae.Radix Angelicae Sinensis, the cloudy blood of Radix Paeoniae Alba tonification moisten body of stomach, and the Hechuan rhizome of chuanxiong nourishes blood and the blood collateral dredging.More than all medicines be ministerial drug altogether.
Poria, the Rhizoma Atractylodis Macrocephalae, Rhizoma Alismatis spleen invigorating eliminating dampness by diuresis; Herba Artemisiae Scopariae, Radix Sanguisorbae clearing away heat and eliminating dampness, Herba Artemisiae Scopariae and energy dispersing the stagnated liver-QI for regulating the stomach; The Rhizoma Acori Graminei removing dampness to restore normal function of the stomach; Rhizoma Corydalis, Pollen Typhae, pseudo-ginseng blood-circulation-invigovating relieve the pain, more than all medicines be adjuvant drug altogether.
Endothelium corneum is gone into the stomach warp, and the stomach function regulating that helps digestion is adjuvant.
Prove that through pharmacodynamic study this medicine can prevent the generation of chronic gastritis, experimental chronic gastritis is had therapeutical effect.Can prevent, treat gastric ulcer, improve the gastric secretory function, two-ways regulation gastric acidity.Do not find toxic and side effects through acute toxicity, long term toxicity test.
Embodiment;
1. Bulbus Lilii 100; Radix Scrophulariae 90; The Radix Linderae 50; Radix Ophiopogonis 90; Radix Angelicae Sinensis 50; The Radix Paeoniae Alba 180; Herba Dendrobii 60; Rhizoma Chuanxiong 60;
2. Bulbus Lilii 90; Radix Scrophulariae 80; The Radix Linderae 60; Radix Ophiopogonis 80; Radix Angelicae Sinensis 50; The Radix Paeoniae Alba 160; Herba Dendrobii 50; Rhizoma Chuanxiong 50;
3. Bulbus Lilii 90; Poria 75; Radix Scrophulariae 75; The Radix Linderae 45; Rhizoma Alismatis 45; Radix Ophiopogonis 90; Radix Angelicae Sinensis 45; Herba Artemisiae Scopariae 60; Rhizoma Corydalis 60; The Radix Paeoniae Alba 150; Herba Dendrobii 45; Rhizoma Acori Graminei 45; Rhizoma Chuanxiong 45; Endothelium corneum 30; Radix Notoginseng 45; The Rhizoma Atractylodis Macrocephalae 60; Radix Sanguisorbae 90; Pollen Typhae 30.
4. Bulbus Lilii 45; Poria 90; Radix Scrophulariae 60; The Radix Linderae 30; Rhizoma Alismatis 30; Radix Ophiopogonis 75; Radix Angelicae Sinensis 30; Herba Artemisiae Scopariae 45; Rhizoma Corydalis 45; The Radix Paeoniae Alba 75; Herba Dendrobii 90; Rhizoma Acori Graminei 30; Rhizoma Chuanxiong 60; Endothelium corneum 15; Radix Notoginseng 15; The Rhizoma Atractylodis Macrocephalae 30; Radix Sanguisorbae 60; Pollen Typhae 45.
5. Bulbus Lilii 60; Poria 60; Radix Scrophulariae 90; The Radix Linderae 60; Rhizoma Alismatis 60; Radix Ophiopogonis 60; Radix Angelicae Sinensis 45; Herba Artemisiae Scopariae 75; Rhizoma Corydalis 75; The Radix Paeoniae Alba 60; Herba Dendrobii 90; Rhizoma Acori Graminei 60; Rhizoma Chuanxiong 30; Endothelium corneum 45; Radix Notoginseng 30; The Rhizoma Atractylodis Macrocephalae 45; Radix Sanguisorbae 45; Pollen Typhae 60.
Preparation method is as follows:
1. make up a prescription
By above-mentioned prescription the each component medicament is weighed.
2. selection
Each medicament is removed earth, choose clean impurity, drying.
3. pulverize
With above each medicament powder be broken into 80 order fine powders, sieve, mixing.
4. pill
Per 100 medicated powder add equivalent refined honey (70 ℃ of honey temperature), make honeyed pill, and the every ball of big honeyed pills weighs 9 grams, and per 10 balls of small honey pill weigh 2 grams.
The medicament of making by the foregoing description shows the clinical treatment that routine chronic atrophic gastritis patient surplus 2500 carries out, effective percentage is up to more than 95%, this medicine not only has the good curing effect to atrophic gastritis, also gastric mucosa intestinalization and atypical hyperplasia there are the elimination effect, the generation that prevents gastric cancer is also had positive effect.
Claims (6)
1. medicament for the treatment of atrophic gastritis is characterized in that it is made by the following weight proportion raw material:
Bulbus Lilii 45-100, Radix Scrophulariae 60-100, Radix Linderae 30-60:
Radix Ophiopogonis 60-100, Radix Angelicae Sinensis 30-60, Radix Paeoniae Alba 75-180
Herba Dendrobii 30-100, Rhizoma Chuanxiong 30-60.
2. the medicament of treatment atrophic gastritis according to claim 1 is characterized in that wherein also can adding:
Poria 45-100, Rhizoma Alismatis 30-60, Herba Artemisiae Scopariae 45-75, Rhizoma Corydalis 45-75,
Rhizoma Acori Graminei 30-60, Endothelium corneum 10-45, Radix Notoginseng 10-45, Rhizoma Atractylodis Macrocephalae 25-60,
Radix Sanguisorbae 45-100, Pollen Typhae 30-75.
3. the medicament of treatment atrophic gastritis according to claim 1 and 2 is characterized in that it can be a dosage form on any pharmaceutics.
4. the medicament of treatment atrophic gastritis according to claim 3 is characterized in that said medicament is a pill.
5. treat the medicaments preparation method that gastritis is given birth in atrophy for one kind, it is characterized in that it is undertaken by following operation:
A. prepare burden
By following proportioning each raw material is weighed:
Bulbus Lilii 45-100, Radix Scrophulariae 60-100, Radix Linderae 30-60,
Radix Ophiopogonis 60-100, Radix Angelicae Sinensis 30-60, Radix Paeoniae Alba 75-180,
Herba Dendrobii 30-100, Rhizoma Chuanxiong 30-60;
B. selection
Each raw material is removed earth, choose clean impurity, drying;
C. pulverize
With above each raw material powder be broken into 80 order fine powders, sieve, mixing;
D. pill
Press medicated powder weight and add the equivalent refined honey, under 70 ℃ of temperature, make honeyed pill.
6. according to the medicaments preparation method of the described treatment atrophic gastritis of claim 5, it is characterized in that also can adding in the said batching: Poria 45-100, Rhizoma Alismatis 30-60, Herba Artemisiae Scopariae 45-75, Rhizoma Corydalis 45-75, Rhizoma Acori Graminei 30-60, Endothelium corneum 10-45; Radix Notoginseng 10-45, Rhizoma Atractylodis Macrocephalae 25-60, Radix Sanguisorbae 45-100, Pollen Typhae 30-75.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00124366A CN1114431C (en) | 2000-09-11 | 2000-09-11 | Medicine for treating atrophic gastritis and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00124366A CN1114431C (en) | 2000-09-11 | 2000-09-11 | Medicine for treating atrophic gastritis and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1286101A CN1286101A (en) | 2001-03-07 |
| CN1114431C true CN1114431C (en) | 2003-07-16 |
Family
ID=4590368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN00124366A Expired - Fee Related CN1114431C (en) | 2000-09-11 | 2000-09-11 | Medicine for treating atrophic gastritis and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1114431C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1315512C (en) * | 2004-12-10 | 2007-05-16 | 赵宏 | Medicine for treating gastritis and its preparation method |
| CN101229323B (en) * | 2008-01-21 | 2014-03-26 | 邯郸制药有限公司 | Lily oral liquid and quality standard and test method of pharmaceutical preparation thereof |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101766790B (en) * | 2010-04-08 | 2011-04-27 | 泰一和浦（北京）中医药研究院有限公司 | Chinese medicine composite for treating chronic atrophic gastritis and preparation method thereof |
| CN103536753B (en) * | 2013-09-28 | 2015-04-08 | 王纯治 | Traditional Chinese medicine mixture for treating chronic gastroenteritis |
| CN105477361B (en) * | 2015-12-16 | 2019-06-28 | 邯郸制药股份有限公司 | A kind of Chinese medicine composition preparation method that treating gastritis and preparation |
| CN105535533A (en) * | 2015-12-30 | 2016-05-04 | 邯郸制药股份有限公司 | Traditional Chinese medicine composition for treatinggastritis |
-
2000
- 2000-09-11 CN CN00124366A patent/CN1114431C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1315512C (en) * | 2004-12-10 | 2007-05-16 | 赵宏 | Medicine for treating gastritis and its preparation method |
| CN101229323B (en) * | 2008-01-21 | 2014-03-26 | 邯郸制药有限公司 | Lily oral liquid and quality standard and test method of pharmaceutical preparation thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1286101A (en) | 2001-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101066445A (en) | Chinese medicine prepn for curing gastropathy radically | |
| CN104225441A (en) | Traditional Chinese medicine composition for treating stomach trouble and preparation method of granules and capsules of traditional Chinese medicine composition | |
| CN1114431C (en) | Medicine for treating atrophic gastritis and its preparing process | |
| CN1850237A (en) | Medicine for treating chronic superficial gastritis and peptic ulcer diseases | |
| CN101062221A (en) | Medicine for treating gastric ulcer and duodenal ulcer | |
| CN102552572B (en) | Chinese medicine for treating appendicitis | |
| CN103191322A (en) | Traditional Chinese medicine for treating severe acute pancreatitis | |
| CN101041047A (en) | Chinese traditional medicine compound took orally for treating chronic superficial gastritis | |
| CN101036758A (en) | Chinese traditional medicine composition took orally for treating chronic superficial gastritis | |
| CN1137404A (en) | Drug for curing pulmonary tuberculosis | |
| CN113209194B (en) | Composition for treating chronic gastritis and preparation method and application thereof | |
| CN104189643A (en) | Osteopathia rehabilitation pill for treating chronic osteomyelitis | |
| CN1185000C (en) | Medicine for treating cyst | |
| CN103223024A (en) | Diabetes mellitus dialectical traditional Chinese medicine prescription | |
| CN1191846C (en) | Medicine for treating stomach disease | |
| CN1299739C (en) | Chinese medicine preparation for treating chronic erosive gastritis and enteritis and preparing method | |
| CN104800772A (en) | Traditional Chinese medicine composition for treating vital-energy-depression type coronary heart disease and application of traditional Chinese medicine composition | |
| CN1277571C (en) | Chinese medicine preparation for stomach diseases | |
| CN1105875A (en) | Medicine for treating ascites due to cirrhosis | |
| CN1110589A (en) | Pill for treating splenico or gastric vital energy deficiency type chronic superficial, atrophic gastritis | |
| CN101028421A (en) | Chinese medicine for treating chronic kidney failure | |
| CN101062286A (en) | Plaster for treating enteritis | |
| CN1742952A (en) | Chinese medicine special for treating chronic atrophic gastritis | |
| CN101670046A (en) | Chinese medicinal composition for gastritis and esophagitis and preparation process thereof | |
| CN1183297A (en) | Katsutoxin pill for tumor and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20030716 Termination date: 20130911 |